Strategies for Precise Modulation of Protein Degradation.

Abstract

ConspectusTargeted protein degradation (TPD) technologies, exemplified by proteolysis-targeting chimeras (PROTACs), have revolutionized therapeutic strategies by facilitating the selective degradation of pathogenic proteins instead of simply inhibiting their functions. This degradation-based strategy offers significant advantages over traditional small-molecule inhibitors, which often block protein activity without eliminating the target. PROTACs function by leveraging the ubiquitin-proteasome system to selectively degrade target proteins, thus enabling the modulation of a broader range of disease-causing proteins including those that were previously considered undruggable. As a result, PROTAC-based therapies have gained considerable attention in drug discovery, especially in oncology, immunology, and neurodegenerative diseases. However, clinical translation of conventional PROTACs remains challenging due to issues such as limited target specificity, poor solubility, inadequate cellular permeability, unfavorable pharmacokinetic profiles, and the absence of spatiotemporal resolution.To address these hurdles, various innovative strategies have been developed to enhance the precision of protein degradation. These approaches focus on improving targeted delivery, solubility, membrane permeability, and spatiotemporal control with the goal of overcoming the inherent limitations of traditional PROTAC designs. For instance, aptamer-conjugated PROTACs have shown great promise by improving tumor selectivity and reducing off-target effects through tumor-specific receptor recognition and subsequent internalization. Moreover, the development of drugtamer-PROTAC conjugates enables more precise codelivery with small-molecule agents, optimizing the synergistic effects of both modalities while minimizing systemic toxicity. Additionally, RGD peptide-based PROTAC conjugation strategies capitalize on the use of tumor-homing peptides to enhance cellular uptake, improve tumor penetration, and increase degradation specificity in tumor cells, further reducing off-target toxicities in healthy tissues.Another critical advancement is the development of photocontrolled PROTACs, which allow for precise temporal regulation of protein degradation in vivo. By leveraging light-responsive molecules, these systems provide the ability to trigger protein degradation at specific time points, offering unparalleled control over therapeutic interventions. Furthermore, theranostic PROTACs, which combine both diagnostic and therapeutic functions, facilitate real-time monitoring of protein degradation events in living cells and animal models, enabling simultaneous assessment of the therapeutic efficacy and biomarker visualization.This Account reviews recent advancements in the design of smart PROTACs, highlighting strategies that improve their tumor specificity, solubility, permeability, and spatiotemporal control. These innovations provide promising solutions to address the limitations of traditional PROTACs, paving the way for progress in drug discovery and the evolution of precision medicine. While the discussed strategies present significant opportunities, we also explore the challenges, limitations, and future directions for clinical translation, offering insights into the potential for degrader-based precision therapies in a clinical setting.